Kimberly Lynn Blackwell, MD

Adjunct Professor in the Department of Medicine
Campus mail Duke Box 3893, Durham, NC 27710
Phone (919) 668-1748
Email address black034@mc.duke.edu

Breast cancer angiogenesis
Breast cancer in younger women
Hormonal therapy
Neoadjurant therapy for breast cancer

Current Clinical Investigations

Principal Investigator, A Phase I-II Study of Neoadjuvant Evacet/Paclitaxel/Hyperthermia in Locally Advanced Breast Cancer Patients.

Investigator, Development of Screening Markers for Breast Cancer using Circulating Immune Complexes: Collaborative Study with Diagen Medical Technologies.

Principal Investigator, Use of Plasma D-Dimer as a Predictive Marker in Colorectal Carcinoma: Correlative Science Study with Genentech, Inc.

Principal Investigator, A randomized, Phase II study of gabapentin or glutamine to prevent the peripheral neuropathy/myalgia associated with weekly taxol administration in metastatic breast and lung cancer.

Investigator, A Phase 2, Randomized, Double-Masked, Multicenter Study of Two Dose Levels of ERA-923 for the treatment of Metastatic Breast Cancer in Postmenopausal Women who have failed Tamoxifen therapy. Genetics Institute.

Investigator, A Phase I Study of Combined Doxil/Hyperthermia in Stage IV Breast Cancer.

Education and Training

  • Fellow in Hematology-Oncology, Medicine, Duke University, 1997 - 2000
  • Medical Resident, Medicine, Duke University, 1994 - 1997
  • M.D., Mayo School of Health Sciences, 1994

Publications

Blackwell, Kimberly, Roman Donskih, C Michael Jones, Allen Nixon, Maria J. Vidal, Roumen Nakov, Pritibha Singh, Gregor Schaffar, Pere Gascón, and Nadia Harbeck. “A Comparison of Proposed Biosimilar LA-EP2006 and Reference Pegfilgrastim for the Prevention of Neutropenia in Patients With Early-Stage Breast Cancer Receiving Myelosuppressive Adjuvant or Neoadjuvant Chemotherapy: Pegfilgrastim Randomized Oncology (Supportive Care) Trial to Evaluate Comparative Treatment (PROTECT-2), a Phase III, Randomized, Double-Blind Trial..” Oncologist 21, no. 7 (July 2016): 789–94. https://doi.org/10.1634/theoncologist.2016-0011.

PMID
27091420
Full Text

Harbeck, Nadia, Oleg Lipatov, Mona Frolova, Dmitry Udovitsa, Eldar Topuzov, Doina Elena Ganea-Motan, Roumen Nakov, Pritibha Singh, Anita Rudy, and Kimberly Blackwell. “Randomized, double-blind study comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer..” Future Oncol 12, no. 11 (June 2016): 1359–67. https://doi.org/10.2217/fon-2016-0016.

PMID
27020170
Full Text

Freedman, Rachel A., Rebecca S. Gelman, Jeffrey S. Wefel, Michelle E. Melisko, Kenneth R. Hess, Roisin M. Connolly, Catherine H. Van Poznak, et al. “Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases..” J Clin Oncol 34, no. 9 (March 20, 2016): 945–52. https://doi.org/10.1200/JCO.2015.63.0343.

PMID
26834058
Full Text

Roe, Matthew T., Derek D. Cyr, Debra Eckart, Phillip J. Schulte, Michael A. Morse, Kimberly L. Blackwell, Neal E. Ready, et al. “Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome..” Eur Heart J 37, no. 4 (January 21, 2016): 412–22. https://doi.org/10.1093/eurheartj/ehv611.

PMID
26637834
Full Text

Blackwell, Kimberly, Howard Burris, Patricia Gomez, N. Lynn Henry, Steven Isakoff, Frank Campana, Lei Gao, Jason Jiang, Sandrine Macé, and Sara M. Tolaney. “Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor..” Breast Cancer Res Treat 154, no. 2 (November 2015): 287–97. https://doi.org/10.1007/s10549-015-3615-9.

PMID
26497877
Full Text

Kimmick, Gretchen, Sara N. Edmond, Hayden B. Bosworth, Jeffrey Peppercorn, Paul K. Marcom, Kimberly Blackwell, Francis J. Keefe, and Rebecca A. Shelby. “Medication taking behaviors among breast cancer patients on adjuvant endocrine therapy..” Breast 24, no. 5 (October 2015): 630–36. https://doi.org/10.1016/j.breast.2015.06.010.

PMID
26189978
Full Text

Blackwell, K., V. Semiglazov, D. Krasnozhon, I. Davidenko, L. Nelyubina, R. Nakov, G. Stiegler, et al. “Comparison of EP2006, a filgrastim biosimilar, to the reference: a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy..” Ann Oncol 26, no. 9 (September 2015): 1948–53. https://doi.org/10.1093/annonc/mdv281.

PMID
26122726
Full Text

Siamakpour-Reihani, Sharareh, Kouros Owzar, Chen Jiang, Peter M. Scarbrough, Oana I. Craciunescu, Janet K. Horton, Holly K. Dressman, Kimberly L. Blackwell, and Mark W. Dewhirst. “Genomic profiling in locally advanced and inflammatory breast cancer and its link to DCE-MRI and overall survival..” Int J Hyperthermia 31, no. 4 (June 2015): 386–95. https://doi.org/10.3109/02656736.2015.1016557.

PMID
25811737
Full Text

Pages